High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease

Clinical Biochemistry

Volumn 48, Issue 4-5, 2015, Pages 302-307

  Bjurman, Christian ^a   Petzold, Max ^b   Venge, Per ^c,d   Farbemo, Julia ^b   Fu, Michael L X ^a   Hammarsten, Ola ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiac biomarkers; Cardiac troponin; Kidney function

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CHROMIUM 51; COPEPTIN; CREATININE; CYSTATIN C; EDETIC ACID; FATTY ACID BINDING PROTEIN; IOHEXOL; TROPONIN; TROPONIN I; TROPONIN T; BRAIN NATRIURETIC PEPTIDE; GLYCOPEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PLASMA CLEARANCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC;

ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; FATTY ACID-BINDING PROTEINS; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TROPONIN I; TROPONIN T;

EID: 84925541572     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.01.008     Document Type: Article

References (42)

1. Hamm C.W., Bassand J.P., Agewall S., Bax J., Boersma E., Bueno H., et al. Esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent st-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
2. Thygesen K., Mair J., Katus H., Plebani M., Venge P., Collinson P., et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010, 31:2197-2204.
3. Viswanathan K., Kilcullen N., Morrell C., Thistlethwaite S.J., Sivananthan M.U., Hassan T.B., et al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol 2010, 55:2590-2598.
4. Carroll C., Al Khalaf M., Stevens J.W., Leaviss J., Goodacre S., Collinson P.O., et al. Heart-type fatty acid binding protein as an early marker for myocardial infarction: systematic review and meta-analysis. Emerg Med J 2013, 30:280-286.
5. Carlsen C.M., Bay M., Kirk V., Gotze J.P., Kober L., Nielsen O.W. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated n-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen hospital heart failure study. Eur J Heart Fail 2012, 14:240-247.
6. Thygesen K., Mair J., Mueller C., Huber K., Weber M., Plebani M., et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the study group on biomarkers in cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012, 33:2001-2006.
7. Terzic D., Johansson-Fällgren A.-S., Ragnarsson O., Goetze J., Hammarsten O. Evaluation of a sensitive copeptin assay for clinical measurement. Open Clin Chem J 2012, 5:21-26.
8. Reichlin T., Hochholzer W., Stelzig C., Laule K., Freidank H., Morgenthaler N.G., et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009, 54:60-68.
9. Maisel A., Mueller C., Neath S.X., Christenson R.H., Morgenthaler N.G., McCord J., et al. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (copeptin helps in the early detection of patients with acute myocardial infarction). J Am Coll Cardiol 2013, 62:150-160.
10. Mockel M., Searle J., Hamm C., Slagman A., Blankenberg S., Huber K., et al. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 2014, [Epub ahead of print]. 10.1093/eurheartj/ehu178.
11. Yalta K., Yalta T., Sivri N., Yetkin E. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013, 167:1750-1759.
12. Members K.B. Chapter 4: other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Inter 2013, Suppl. 3. (http://www.nature.com/kisup/journal/v3/n1/index.html:91-111).
13. Palazzuoli A., Masson S., Ronco C., Maisel A. Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev 2014, 19:267-284.
14. Waldum B., Os I. The cardiorenal syndrome: what the cardiologist needs to know. Cardiology 2013, 126:175-186.
15. Pfortmueller C.A., Funk G.C., Marti G., Leichtle A.B., Fiedler G.M., Schwarz C., et al. Diagnostic performance of high-sensitive troponin t in patients with renal insufficiency. Am J Cardiol 2013, 112:1968-1972.
16. Brandstrom E., Grzegorczyk A., Jacobsson L., Friberg P., Lindahl A., Aurell M. Gfr measurement with iohexol and 51cr-edta. A comparison of the two favoured gfr markers in Europe. Nephrol Dial Transplant 1998, 13:1176-1182.
17. Filler G., Bokenkamp A., Hofmann W., Le Bricon T., Martinez-Bru C., Grubb A. Cystatin c as a marker of gfr-history, indications, and future research. Clin Biochem 2005, 38:1-8.
18. Rule A.D., Bailey K.R., Lieske J.C., Peyser P.A., Turner S.T. Estimating the glomerular filtration rate from serum creatinine is better than from cystatin c for evaluating risk factors associated with chronic kidney disease. Kidney Int 2013, 83:1169-1176.
19. White C., Akbari A., Hussain N., Dinh L., Filler G., Lepage N., et al. Estimating glomerular filtration rate in kidney transplantation: a comparison between serum creatinine and cystatin c-based methods. J Am Soc Nephrol 2005, 16:3763-3770.
20. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130:461-470.
21. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
22. Hasegawa M., Ishii J., Kitagawa F., Kanayama K., Takahashi H., Ozaki Y., et al. Prognostic value of highly sensitive troponin t on cardiac events in patients with chronic kidney disease not on dialysis. Heart Vessel 2013, 28:473-479.
23. Dubin R.F., Li Y., He J., Jaar B.G., Kallem R., Lash J.P., et al. Predictors of high sensitivity cardiac troponin t in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (cric). BMC Nephrol 2013, 14:229.
24. Vickery S., Price C.P., John R.I., Abbas N.A., Webb M.C., Kempson M.E., et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005, 46:610-620.
25. Anwaruddin S., Lloyd-Jones D.M., Baggish A., Chen A., Krauser D., Tung R., et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the proBNP investigation of dyspnea in the emergency department (pride) study. J Am Coll Cardiol 2006, 47:91-97.
26. Lippi G., Cervellin G. High-sensitivity troponin t is more susceptible than high-sensitivity troponin i to impaired renal function. Am J Cardiol 2013, 112:1985.
27. van Kimmenade R.R., Januzzi J.L., Bakker J.A., Houben A.J., Rennenberg R., Kroon A.A., et al. Renal clearance of b-type natriuretic peptide and amino terminal pro-b-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009, 53:884-890.
28. Tsutamoto T., Wada A., Sakai H., Ishikawa C., Tanaka T., Hayashi M., et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006, 47:582-586.
29. Manzano-Fernandez S., Januzzi J.L., Boronat-Garcia M., Pastor P., Albaladejo-Oton M.D., Garrido I.P., et al. Impact of kidney dysfunction on plasma and urinary n-terminal pro-b-type natriuretic peptide in patients with acute heart failure. Congest Heart Fail 2010, 16:214-220.
30. DeFilippi C., van Kimmenade R.R., Pinto Y.M. Amino-terminal pro-b-type natriuretic peptide testing in renal disease. Am J Cardiol 2008, 101:82-88.
31. Bosselmann H., Egstrup M., Rossing K., Gustafsson I., Gustafsson F., Tonder N., et al. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study. Int J Cardiol 2013, 170:202-207.
32. Lappalainen H., Tiula E., Uotila L., Manttari M. Elimination kinetics of myoglobin and creatine kinase in rhabdomyolysis: implications for follow-up. Crit Care Med 2002, 30:2212-2215.
33. Hallgren R., Karlsson F.A., Roxin L.E., Venge P. Myoglobin turnover-influence of renal and extrarenal factors. J Lab Clin Med 1978, 91:246-254.
34. Wakabayashi Y., Kikuno T., Ohwada T., Kikawada R. Rapid fall in blood myoglobin in massive rhabdomyolysis and acute renal failure. Intensive Care Med 1994, 20:109-112.
35. Pluddemann A., Neyen C., Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods 2007, 43:207-217.
36. Shlipak M.G., Mattes M.D., Peralta C.A. Update on cystatin c: incorporation into clinical practice. Am J Kidney Dis 2013, 62:595-603.
37. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., Wallentin L. Cystatin c: a novel predictor of outcome in suspected or confirmed non-st-elevation acute coronary syndrome. Circulation 2004, 110:2342-2348.
38. Lassus J., Harjola V.P. Cystatin c: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2012, 17:251-261.
39. Lassus J., Harjola V.P., Sund R., Siirila-Waris K., Melin J., Peuhkurinen K., et al. Prognostic value of cystatin c in acute heart failure in relation to other markers of renal function and nt-probnp. Eur Heart J 2007, 28:1841-1847.
40. Shlipak M.G., Matsushita K., Arnlov J., Inker L.A., Katz R., Polkinghorne K.R., et al. Cystatin c versus creatinine in determining risk based on kidney function. N Engl J Med 2013, 369:932-943.
41. Muntner P., Mann D., Winston J., Bansilal S., Farkouh M.E. Serum cystatin c and increased coronary heart disease prevalence in us adults without chronic kidney disease. Am J Cardiol 2008, 102:54-57.
42. Menon V., Shlipak M.G., Wang X., Coresh J., Greene T., Stevens L., et al. Cystatin c as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007, 147:19-27.